Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry

Behavioural Brain Research

Volumn 267, Issue , 2014, Pages 6-11

  Schilling, Jan M ^a,b   Cui, Weihua ^a,b,c   Godoy, Joseph C ^a,b,c,d   Risbrough, Victoria B ^a,d   Niesman, Ingrid R ^a,b   Roth, David M ^a,b   Patel, Piyush M ^a,b   Drummond, John C ^a,b   Patel, Hemal H ^a,b   Zemljic Harpf, Alice E ^a,b   Head, Brian P ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b University of California   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atorvastatin; Brain; Cholesterol; Hypercholesterolemia; Lipid; Pharmacology

Indexed keywords

ATORVA; ATORVASTATIN; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; SYNTAXIN 1; SYNTAXIN 1ALPHA; UNCLASSIFIED DRUG; DLGH4 PROTEIN, MOUSE; GUANYLATE KINASE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; PYRROLE DERIVATIVE; STX1A PROTEIN, MOUSE; SYP PROTEIN, MOUSE;

ARTICLE; BARNES MAZE TEST; BEHAVIOR CHANGE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; LIPID RAFT; LONG TERM CARE; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; ROTAROD TEST; STARTLE REFLEX; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECTS; MAZE TEST; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; TIME;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; EXPLORATORY BEHAVIOR; GUANYLATE KINASE; HEPTANOIC ACIDS; HIPPOCAMPUS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAZE LEARNING; MEMBRANE PROTEINS; MICE, INBRED C57BL; MOTOR ACTIVITY; PYRROLES; REFLEX, STARTLE; SYNAPTOPHYSIN; SYNTAXIN 1; TIME FACTORS;

EID: 84897403599     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.03.014     Document Type: Article

References (29)

1. Liscum L., Cummings R.D., Anderson R.G., DeMartino G.N., Goldstein J.L., Brown M.S. 3-Hydroxy-3-methylglutaryl-CoA reductase: a transmembrane glycoprotein of the endoplasmic reticulum with N-linked high-mannose oligosaccharides. Proc Natl Acad Sci U S A 1983, 80:7165-7169.
2. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J Am Med Assoc 1999, 282:2340-2346.
3. Taylor F., Ward K., Moore T.H., Burke M., Davey Smith G., Casas J.-P., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD004816.
4. Maningat P., Breslow J.L. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011, 365:2250-2251.
5. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
6. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002, 59:223-227.
7. Swiger K.J., Manalac R.J., Blumenthal R.S., Blaha M.J., Martin S.S. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013, 88:1213-1221.
8. Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004, 117:823-829.
9. Wagstaff L.R., Mitton M.W., Arvik B.M., Doraiswamy P.M. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
10. Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009, 29:800-811.
11. Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964.
12. Padala K.P., Padala P.R., McNeilly D.P., Geske J.A., Sullivan D.H., Potter J.F. The effect of HMG: CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge Pilot study. Am J Geriatr Pharmacother 2012, 10:296-302.
13. U.S. Food Drug Administration. FDA expands advice on statins risk [actualized 29 Feb 2012], drug administration. FDA expands advice on statins risk [actualized 29 Feb 2012] (no date).
14. Bulloj A., Leal M.C., Surace E.I., Zhang X., Xu H., Ledesma M.D., et al. Detergent resistant membrane-associated IDE in brain tissue and cultured cells: relevance to Abeta and insulin degradation. Mol Neurodegener 2008, 3:22.
15. King D.S., Wilburn A.J., Wofford M.R., Harrell T.K., Lindley B.J., Jones D.W. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003, 23:1663-1667.
16. Liao Y., Zhao H., Ogai A., Kato H., Asakura M., Kim J., et al. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008, 31:335-344.
17. Risbrough V.B., Geyer M.A., Hauger R.L., Coste S., Stenzel-Poore M., Wurst W., et al. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 2009, 34:1494-1503.
18. Head B.P., Peart J.N., Panneerselvam M., Yokoyama T., Pearn M.L., Niesman I.R., et al. Loss of caveolin-1 accelerates neurodegeneration and aging. PLoS One 2010, 5:e15697.
19. Linetti A., Fratangeli A., Taverna E., Valnegri P., Francolini M., Cappello V., et al. Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci 2010, 123:595-605.
20. Sebastião A.M., Colino-Oliveira M., Assaife-Lopes N., Dias R.B., Ribeiro J.A. Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases. Neuropharmacology 2013, 64:97-107.
21. Kwon S.E., Chapman E.R. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron 2011, 70:847-854.
22. Biondi E. Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider. Neurol Sci 2011, 32:195-201.
23. Botti R.E., Triscari J., Pan H.Y., Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991, 14:256-261.
24. Andersson M., Elmberger P.G., Edlund C., Kristensson K., Dallner G. Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS Lett 1990, 269:15-18.
25. Galatti L., Polimeni G., Salvo F., Romani M., Sessa A., Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006, 26:1190-1192.
26. Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D'Agostino R.B., Gibbons R., et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013, PMID: 24222018.
27. Stone N.J., Robinson J., Lichtenstein A.H., Merz C.N.B., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, PMID: 24222016.
28. Schmitt U., Tanimoto N., Seeliger M., Schaeffel F., Leube R.E. Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience 2009, 162:234-243.
29. Kelley B.J., Glasser S. Cognitive effects of statin medications. CNS Drugs 2014, PMID: 24504830.